Silexion Therapeutics announces the selection of AMS Advanced Medical Services GmbH as the CRO to support upcoming Phase 2/3 clinical trials for SIL204, targeting KRAS-driven solid tumor cancers.
AMS brings over 28 years of drug development experience and proven Phase 3 oncology trial expertise to the partnership with Silexion.
The partnership is expected to facilitate regulatory submissions, with Phase 2/3 trials set to begin in the first half of 2026.
CRO Selection Milestone
Selecting AMS marks a critical milestone in advancing SIL204 towards clinical development, enhancing regulatory knowledge and oncology expertise for Silexion.
Positive Preclinical Results
Recent preclinical studies demonstrate SIL204's effectiveness across multiple cancer models, showing up to 97% inhibition rates in pancreatic cancer cells with KRAS mutations.
Innovative Dual-Route Administration
The upcoming Phase 2/3 trial will evaluate SIL204's dual-route administration strategy targeting both primary tumors and metastatic disease in pancreatic cancer patients.
- SIL204 has recently shown up to 97% inhibition in preclinical studies across various cancer types, indicating promising outcomes for patients with KRAS-driven cancers.
- The CRO partnership with AMS brings decades of experience and expertise in managing complex international clinical trials, strengthening Silexion's position in advancing RNA interference therapies.
With the selection of AMS as the CRO, Silexion Therapeutics is poised to accelerate the development of SIL204, a potentially transformative RNAi therapy for KRAS-driven cancers, bringing hope to patients in need of innovative treatment options.